Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Searle presents new series of potent and selective vitronectin receptor antagonists

Oct. 7, 1999

ASBMR news: preclinical and clinical studies support efficacy, safety of Amgen's OPG

Oct. 7, 1999

Dual glucagon antagonists/cytokine inhibitors in the Merck pipeline

Oct. 7, 1999

Ares-Serono files for approval of new infertility treatment

Oct. 7, 1999

Meta-analysis establishes higher pregnancy rates with rFSH than with uFSH

Oct. 7, 1999

Dompe identifies lead tartronate derivative for development as antiosteopenic agent

Oct. 7, 1999

TheraTech and Procter & Gamble rework agreements for female HRT products

Oct. 6, 1999

TAK-778, the first nonendogenous compound able to promote new bone formation and heal breaks

Oct. 6, 1999

Potent and selective vitronectin antagonists developed at SmithKline Beecham

Oct. 6, 1999

First launch for Bone Care's novel vitamin D prohormone

Oct. 6, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...